JPRN-jRCT2031230217招募中2 期
[M22-056] A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with An ActiveTreatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine
Otani Tetsuya0 个研究点目标入组 520 人开始时间: 2023年7月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •At least a 1-year history of migraine (with or without aura).
- •- Less than 50 years of age at the time of migraine onset.
- •- History of 4 to 14 migraine days per month in the 3 months prior to screening.
- •- 4 to 14 migraine days in the baseline period and completed at least 20 out of 28 days at the baseline periodper the eDiary.
排除标准
- •- Difficulty with distinguishing migraine headaches from tension-type or other headaches.
- •- Clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
研究者
相似试验
招募中
3 期
Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)CTRI/2023/08/056910BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
招募中
3 期
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combinationwith Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma:SUCCESSOR-2Multiple MyelomaJPRN-jRCT2071230095Engelhardt Brian41
招募中
1 期
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2Relapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2022-500861-29-00Celgene Corp.493
进行中（未招募）
1 期
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, and Dexamethasone in patients with a non-responsive or progressive blood cancer called Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000431-49-SECelgene Corporation864
进行中（未招募）
1 期
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.EUCTR2021-001957-30-FICelgene Corporation950